Interleukin 1 receptor antagonist; gene polymorphism and restenosis after coronary angioplasty

Heart

Volumn 86, Issue 3, 2001, Pages 336-340

  Francis, S E ^a   Camp, N J ^b   Burton, A J ^a   Dewberry, R M ^a   Gunn, J ^a   Stephens Lloyd, A ^c   Cumberland, D C ^a   Gershlick, A ^c   Crossman, D C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Angioplasty; Inflammation; Interleukin 1 receptor antagonist; Restenosis

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DNA POLYMORPHISM; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOSITY; HUMAN; INFLAMMATION; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VARIABLE NUMBER OF TANDEM REPEAT; WOUND HEALING;

EID: 0034861338     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.86.3.336     Document Type: Article

References (32)

1. Restenosis
2. Contributions of frequency distribution analysis to the understanding of coronary restenosis: A reappraisal of the gaussian curve
3. Effect of restenosis at one previously dilated coronary site on the probability of restenosis at another previously dilated coronary site
4. Insertion deletion polymorphism in the ACE gene and risk of restenosis after coronary angioplasty
5. A potent genetic risk factor for restenosis
6. Angiotensin-converting enzyme insertion deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris
7. Not the ACE polymorphism, but the E-selectin gene polymorphism helps to predict restenosis after coronary angioplasty
8. Role of platelet glycoprotein PL A1/A2 polymorphism in restenosis after percutaneous transluminal coronary angioplasty
9. P1 A1/A2 polymorphism of glycoprotein III1 and risk of coronary artery disease and restenosis following coronary angioplasty
10. Apoplipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty
11. Risk of clinical restenosis after PTCA is influenced by a common functional variant in the human stromelysin promoter
12. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty
13. Atherosclerosis - An inflammatory disease
14. Temporal and spatial distribution of IL-1β in balloon injured coronary arteries
15. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease
16. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: Evidence of inflammatory responses in coronary angioplasty
17. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment
18. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1ra) gene polymorphism
19. Monokine antagonism is reduced in patients with IDDM
20. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1β on tuberculosis
21. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment
22. Allele 2 of IL-1RN gene polymorphism is associated with reduced expression of IL-1ra in ulcerative colitis
23. Interleukin-1 receptor antagonist (IL-1ra) in human endothelial cells and diseased coronary arteries
24. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers
25. Association of interleukin-1 gene variants and carotid arterial wall thickness: The ARIC study
26. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting
27. Interleukin-1 and interleukin-1 antagonism
28. Purification and characterisation of a novel soluble receptor for interleukin-1
29. Soluble type II interleukin-1 receptor binds and blocks the processing of IL-1B precursors and loses affinity for IL-1 receptor antagonist
30. Interleukin-1 receptor antagonist
31. Differential effects of interleukin-1 receptor antagonist and tumour necrosis binding protein on fatty streak formation in apoE-deficient mice
32. Arterial inflammation in mice lacking the interleukin-1 receptor antagonist gene